Disease modification in osteoarthritis: are we there yet?

Area of Science:

• Orthopedics
• Pharmacology
• Rheumatology

Background:

• Osteoarthritis (OA) is a degenerative joint disease causing significant disability.
• Current OA treatments primarily manage symptoms, not disease progression.
• Disease-modifying osteoarthritis drugs (DMOADs) represent a new therapeutic class targeting OA pathophysiology.

Purpose of the Study:

• To review the current landscape of DMOADs in late-stage clinical development.
• To highlight pharmacologic agents in phase 2 and phase 3 trials for OA.

Main Methods:

• Narrative review of scientific literature and clinical trial databases.
• Focus on DMOAD candidates in advanced stages of development (Phase 2/3).

Main Results:

• Several DMOAD candidates are progressing through late-stage clinical trials.
• These agents target various OA mechanisms, including inflammation and structural damage.
• Potential for both structural modification and symptomatic relief exists.

Conclusions:

• Late-stage DMOAD development shows promise for altering OA's natural course.
• These novel therapies could significantly reduce long-term OA-related disability.
• Further research and clinical validation are crucial for DMOADs.